bpc-157 not approved for human use fda statement BPC-157: Experimental Peptide Creates Risk Athletes FDA panel votes to place

NF-B Targeting Tripeptide & Barrier Peptide KPV (Lys-Pro-Val) is a C-terminal tripeptide of -melanocyte-stimulating hormone with potent, selective anti-inflammatory activity mediated primarily through NF-B pathway inhibition

Compound Specifications CAS 137525-51-0 MW 1,419.53 Da Documentation & Lab Use Form: Lyophilized research material Documentation: Review the product label, batch records, and applicable laboratory SOPs before accessioning

By pairing the synthetic pentadecapeptide with an L-Arginine protective buffer, the compound exhibits an exceptional oral bioavailability profile exceeding 90%

Molecules 19:1080310817 Tang TS, Cardella D, Lander AJ, Li X, Escudero JS, Tsai Y-H, Luk LY (2020) Use of an asparaginyl endopeptidase for chemo-enzymatic peptide and protein labeling